Publications by authors named "Juan Carlos Ruiz Cobo"
Acute hepatitis E virus (HEV) infection is typically self-limiting and has a favourable prognosis. However, certain populations such as patients with pre-existing chronic liver disease may experience severe manifestations, including progression to acute-on-chronic liver failure (ACLF). Among viral hepatitis types, hepatitis A, E, and B are major causes of ACLF.
View Article and Find Full Text PDFBackground: The WHO has set a goal to decrease viral hepatitis-related fatalities by 65% by 2030.
Aims: To locate and retrieve to care all individuals diagnosed with hepatitis B, D or C, and investigate why they were not linked to appropriate medical management.
Methods: We conducted a retrospective-prospective search for patients with hepatitis B, D or C virus (HBV, HDV and HCV) infection in the central laboratory database of the Barcelona northern health area (catchment population, 450,000).
Background And Aims: Small series suggest that rituximab could be effective as treatment for autoimmune hepatitis (AIH), although data are scarce. We aimed to evaluate the efficacy and safety of rituximab in different cohorts of patients with AIH.
Methods: Multicentre retrospective analysis of the 35 patients with AIH and its variant forms treated with rituximab and included in the ColHai registry between 2015 and 2023.
Article Synopsis
- * Current guidelines for treating AKI, like stopping diuretics and using albumin for fluid management, may not always be helpful and can sometimes worsen the patient's condition, leading to complications like fluid overload.
- * New techniques, such as hemodynamic point-of-care ultrasound (PoCUS), offer a better way to assess a patient’s fluid status and tailor treatments more effectively, without invasive procedures.
Background: Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first-line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB).
View Article and Find Full Text PDFAn algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury.
Aliment Pharmacol Ther
April 2024
Background: There are few data on corticosteroids (CS)-sparing strategies for checkpoint inhibitor (ICI)-induced liver injury (ChILI).
Aim: We aimed to assess the performance of a 2-step algorithm for severe ChILI, based on ICI temporary discontinuation (step-1) and, if lack of biochemical improvement, CS based on the degree of necroinflammation at biopsy (step-2).
Methods: Prospective study that included all subjects with grade 3/4 ChILI.
Article Synopsis
- Many individuals with Hepatitis C virus (HCV) and Hepatitis B virus (HBV) infections are unaware of their conditions, especially vulnerable populations who struggle with access to healthcare; emergency departments often serve as their only healthcare point of contact.
- A study conducted in emergency departments tested over 17,500 adults for HBsAg and HCV antibodies, discovering a higher prevalence than in the general population, with a significant percentage of positive cases previously unaware of their infections and successfully linking many to care.
- The screening program demonstrated cost-effectiveness, notably in individuals aged 40-70 with HCV, suggesting that emergency department screenings could improve health outcomes and provide a cost-efficient intervention for viral hepatitis.
Background And Aims: Patients with hepatitis C virus (HCV) and advanced fibrosis remain at risk of hepatocellular carcinoma (HCC) after sustained viral response (SVR) and need lifelong surveillance. Because HCC risk is not homogenous and may decrease with fibrosis regression, we aimed to identify patients with low HCC risk based on the prediction of noninvasive markers and its changes after SVR.
Approach And Results: This is a multicenter cohort study, including patients with HCV and compensated advanced fibrosis that achieved SVR after direct antivirals.